{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T20:19:45Z","timestamp":1790108385045,"version":"4.0.1"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,12,20]],"date-time":"2019-12-20T00:00:00Z","timestamp":1576800000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,12,20]],"date-time":"2019-12-20T00:00:00Z","timestamp":1576800000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Faculty of Pharmacy, Chiang Mai University"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>We performed a network meta-analysis of randomised controlled trials (RCTs) and non-randomised studies in adult peritoneal dialysis patients to evaluate the effects of specific renin-angiotensin aldosterone systems (RAAS) blockade classes on residual kidney function and peritoneal membrane function. Key outcome parameters included the following: residual glomerular filtration rate (rGFR), urine volume, anuria, dialysate-to-plasma creatinine ratio (D\/P Cr), and acceptability of treatment. Indirect treatment effects were compared using random-effects model. Pooled standardised mean differences (SMDs) and odd ratios (ORs) were estimated with 95% confidence intervals (CIs). We identified 10 RCTs (n\u2009=\u2009484) and 10 non-randomised studies (n\u2009=\u20093,305). Regarding changes in rGFR, RAAS blockade with angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin II receptor blockers (ARBs) were more efficacious than active control (SMD 0.55 [0.06\u20131.04] and 0.62 [0.19\u20131.04], respectively) with the protective effect on rGFR observed only after usage \u226512 months, and no differences among ACEIs and ARBs. Compared with active control, only ACEIs showed a significantly decreased risk of anuria (OR 0.62 [0.41\u20130.95]). No difference among treatments for urine volume and acceptability of treatment were observed, whereas evidence for D\/P Cr is inconclusive. The small number of randomised studies and differences in outcome definitions used may limit the quality of the evidence.<\/jats:p>","DOI":"10.1038\/s41598-019-55561-5","type":"journal-article","created":{"date-parts":[[2019,12,20]],"date-time":"2019-12-20T11:03:50Z","timestamp":1576839830000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Effectiveness of Renin-Angiotensin-Aldosterone System Blockade on Residual Kidney Function and Peritoneal Membrane Function in Peritoneal Dialysis Patients: A Network Meta-Analysis"],"prefix":"10.1038","volume":"9","author":[{"given":"Sirayut","family":"Phatthanasobhon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1100-7171","authenticated-orcid":false,"given":"Surapon","family":"Nochaiwong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4738-8447","authenticated-orcid":false,"given":"Kednapa","family":"Thavorn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5783-8766","authenticated-orcid":false,"given":"Kajohnsak","family":"Noppakun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Setthapon","family":"Panyathong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuttitham","family":"Suteeka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Hutton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manish M.","family":"Sood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Greg A.","family":"Knoll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7927-1425","authenticated-orcid":false,"given":"Chidchanok","family":"Ruengorn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,12,20]]},"reference":[{"key":"55561_CR1","doi-asserted-by":"publisher","first-page":"3238","DOI":"10.1681\/ASN.2016010112","volume":"27","author":"R Mehrotra","year":"2016","unstructured":"Mehrotra, R., Devuyst, O., Davies, S. J. & Johnson, D. W. The Current State of Peritoneal Dialysis. J Am Soc Nephrol. 27, 3238\u20133252 (2016).","journal-title":"J Am Soc Nephrol."},{"key":"55561_CR2","doi-asserted-by":"crossref","unstructured":"Williams, J. D., Craig, K. J., von Ruhland, C., Topley, N. & Williams, G. T. The natural course of peritoneal membrane biology during peritoneal dialysis. Kidney Int Suppl. S43\u201349 (2003).","DOI":"10.1046\/j.1523-1755.2003.08805.x"},{"key":"55561_CR3","doi-asserted-by":"crossref","first-page":"2158","DOI":"10.1681\/ASN.V12102158","volume":"12","author":"JM Bargman","year":"2001","unstructured":"Bargman, J. M., Thorpe, K. E. & Churchill, D. N. Relative contribution of residual renal function and peritoneal clearance to adequacy of dialysis: a reanalysis of the CANUSA study. J Am Soc Nephrol. 12, 2158\u20132162 (2001).","journal-title":"J Am Soc Nephrol."},{"key":"55561_CR4","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1016\/S0272-6386(03)00362-7","volume":"41","author":"F Termorshuizen","year":"2003","unstructured":"Termorshuizen, F. et al. The relative importance of residual renal function compared with peritoneal clearance for patient survival and quality of life: an analysis of the Netherlands Cooperative Study on the Adequacy of Dialysis (NECOSAD)-2. Am J Kidney Dis. 41, 1293\u20131302 (2003).","journal-title":"Am J Kidney Dis."},{"key":"55561_CR5","doi-asserted-by":"publisher","first-page":"2978","DOI":"10.1093\/ndt\/gfq856","volume":"26","author":"WM van der Wal","year":"2011","unstructured":"van der Wal, W. M. et al. Full loss of residual renal function causes higher mortality in dialysis patients; findings from a marginal structural model. Nephrol Dial Transplant. 26, 2978\u20132983 (2011).","journal-title":"Nephrol Dial Transplant."},{"key":"55561_CR6","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/ki.1990.231","volume":"38","author":"O Heimburger","year":"1990","unstructured":"Heimburger, O., Waniewski, J., Werynski, A., Tranaeus, A. & Lindholm, B. Peritoneal transport in CAPD patients with permanent loss of ultrafiltration capacity. Kidney Int. 38, 495\u2013506 (1990).","journal-title":"Kidney Int."},{"key":"55561_CR7","doi-asserted-by":"crossref","first-page":"S83","DOI":"10.1177\/089686089901902S13","volume":"Suppl 2","author":"O Heimburger","year":"1999","unstructured":"Heimburger, O., Wang, T. & Lindholm, B. Alterations in water and solute transport with time on peritoneal dialysis. Perit Dial Int. 19 Suppl 2, S83\u201390 (1999).","journal-title":"Perit Dial Int. 19"},{"key":"55561_CR8","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.1177\/089686089901903S03","volume":"Suppl 3","author":"Y Kawaguchi","year":"1999","unstructured":"Kawaguchi, Y. National comparisons: optimal peritoneal dialysis outcomes among Japanese patients. Perit Dial Int. 19 Suppl 3, S9\u201316 (1999).","journal-title":"Perit Dial Int. 19"},{"key":"55561_CR9","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1038\/nrneph.2013.43","volume":"9","author":"SJ Nessim","year":"2013","unstructured":"Nessim, S. J. & Bargman, J. M. The peritoneal-renal syndrome. Nat Rev Nephrol. 9, 302\u2013306 (2013).","journal-title":"Nat Rev Nephrol."},{"key":"55561_CR10","doi-asserted-by":"crossref","unstructured":"Marron, B., Remon, C., Perez-Fontan, M., Quiros, P. & Ortiz, A. Benefits of preserving residual renal function in peritoneal dialysis. Kidney Int Suppl. S42\u201351 (2008).","DOI":"10.1038\/sj.ki.5002600"},{"key":"55561_CR11","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1681\/ASN.V113556","volume":"11","author":"LM Moist","year":"2000","unstructured":"Moist, L. M. et al. Predictors of loss of residual renal function among new dialysis patients. J Am Soc Nephrol. 11, 556\u2013564 (2000).","journal-title":"J Am Soc Nephrol."},{"key":"55561_CR12","doi-asserted-by":"publisher","first-page":"105","DOI":"10.7326\/0003-4819-139-2-200307150-00010","volume":"139","author":"PK Li","year":"2003","unstructured":"Li, P. K., Chow, K. M., Wong, T. Y., Leung, C. B. & Szeto, C. C. Effects of an angiotensin-converting enzyme inhibitor on residual renal function in patients receiving peritoneal dialysis. A randomized, controlled study. Ann Intern Med. 139, 105\u2013112 (2003).","journal-title":"Ann Intern Med."},{"key":"55561_CR13","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1053\/j.ajkd.2004.01.019","volume":"43","author":"H Suzuki","year":"2004","unstructured":"Suzuki, H., Kanno, Y., Sugahara, S., Okada, H. & Nakamoto, H. Effects of an angiotensin II receptor blocker, valsartan, on residual renal function in patients on CAPD. Am J Kidney Dis. 43, 1056\u20131064 (2004).","journal-title":"Am J Kidney Dis."},{"key":"55561_CR14","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1681\/ASN.2013030273","volume":"25","author":"Y Ito","year":"2014","unstructured":"Ito, Y. et al. Long-term effects of spironolactone in peritoneal dialysis patients. J Am Soc Nephrol. 25, 1094\u20131102 (2014).","journal-title":"J Am Soc Nephrol."},{"key":"55561_CR15","first-page":"5","volume":"30","author":"B Yelken","year":"2014","unstructured":"Yelken, B. et al. Effects of spironolactone on residual renal function and peritoneal function in peritoneal dialysis patients. Adv Perit Dial. 30, 5\u201310 (2014).","journal-title":"Adv Perit Dial."},{"issue":"Suppl 3","key":"55561_CR16","doi-asserted-by":"crossref","first-page":"S83","DOI":"10.1177\/089686080802803s17","volume":"28","author":"H Nakamoto","year":"2008","unstructured":"Nakamoto, H. et al. Role of the renin-angiotensin system in the pathogenesis of peritoneal fibrosis. Perit Dial Int. 28(Suppl 3), S83\u201387 (2008).","journal-title":"Perit Dial Int."},{"key":"55561_CR17","doi-asserted-by":"publisher","first-page":"F1084","DOI":"10.1152\/ajprenal.00565.2007","volume":"294","author":"H Nishimura","year":"2008","unstructured":"Nishimura, H. et al. Mineralocorticoid receptor blockade ameliorates peritoneal fibrosis in new rat peritonitis model. Am J Physiol Renal Physiol. 294, F1084\u20131093 (2008).","journal-title":"Am J Physiol Renal Physiol."},{"key":"55561_CR18","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1016\/j.cca.2010.02.059","volume":"411","author":"D Yamamoto","year":"2010","unstructured":"Yamamoto, D., Takai, S., Hirahara, I. & Kusano, E. Captopril directly inhibits matrix metalloproteinase-2 activity in continuous ambulatory peritoneal dialysis therapy. Clin Chim Acta. 411, 762\u2013764 (2010).","journal-title":"Clin Chim Acta."},{"key":"55561_CR19","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1093\/ndt\/gfn421","volume":"24","author":"I Kolesnyk","year":"2009","unstructured":"Kolesnyk, I., Noordzij, M., Dekker, F. W., Boeschoten, E. W. & Krediet, R. T. A positive effect of AII inhibitors on peritoneal membrane function in long-term PD patients. Nephrol Dial Transplant. 24, 272\u2013277 (2009).","journal-title":"Nephrol Dial Transplant."},{"key":"55561_CR20","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1177\/089686080502500614","volume":"25","author":"E Rojas-Campos","year":"2005","unstructured":"Rojas-Campos, E. et al. Effect of oral administration of losartan, prazosin, and verapamil on peritoneal solute transport in continuous ambulatory peritoneal dialysis patients. Perit Dial Int. 25, 576\u2013582 (2005).","journal-title":"Perit Dial Int."},{"key":"55561_CR21","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1159\/000095361","volume":"24","author":"R Furuya","year":"2006","unstructured":"Furuya, R., Odamaki, M., Kumagai, H. & Hishida, A. Impact of angiotensin II receptor blocker on plasma levels of adiponectin and advanced oxidation protein products in peritoneal dialysis patients. Blood Purif. 24, 445\u2013450 (2006).","journal-title":"Blood Purif."},{"key":"55561_CR22","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1111\/j.1440-1797.2009.01162.x","volume":"15","author":"S Jing","year":"2010","unstructured":"Jing, S., Kezhou, Y., Hong, Z., Qun, W. & Rong, W. Effect of renin-angiotensin system inhibitors on prevention of peritoneal fibrosis in peritoneal dialysis patients. Nephrology (Carlton). 15, 27\u201332 (2010).","journal-title":"Nephrology (Carlton)."},{"key":"55561_CR23","doi-asserted-by":"publisher","first-page":"53","DOI":"10.3747\/pdi.2009.00088","volume":"31","author":"I Kolesnyk","year":"2011","unstructured":"Kolesnyk, I., Noordzij, M., Dekker, F. W., Boeschoten, E. W. & Krediet, R. T. Treatment with angiotensin II inhibitors and residual renal function in peritoneal dialysis patients. Perit Dial Int. 31, 53\u201359 (2011).","journal-title":"Perit Dial Int."},{"key":"55561_CR24","doi-asserted-by":"publisher","first-page":"877","DOI":"10.6061\/clinics\/2012(08)04","volume":"67","author":"T Basturk","year":"2012","unstructured":"Basturk, T. et al. The effects of angiotensin-converting enzyme inhibitors on peritoneal protein loss and solute transport in peritoneal dialysis patients. Clinics (Sao Paulo). 67, 877\u2013883 (2012).","journal-title":"Clinics (Sao Paulo)."},{"key":"55561_CR25","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1111\/1744-9987.12219","volume":"19","author":"S Yongsiri","year":"2015","unstructured":"Yongsiri, S. et al. Randomized, double-blind, placebo-controlled trial of spironolactone for hypokalemia in continuous ambulatory peritoneal dialysis patients. Ther Apher Dial. 19, 81\u201386 (2015).","journal-title":"Ther Apher Dial."},{"key":"55561_CR26","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1186\/s12882-017-0616-4","volume":"18","author":"JI Shen","year":"2017","unstructured":"Shen, J. I., Saxena, A. B., Vangala, S., Dhaliwal, S. K. & Winkelmayer, W. C. Renin-angiotensin system blockers and residual kidney function loss in patients initiating peritoneal dialysis: an observational cohort study. BMC Nephrol. 18, 196 (2017).","journal-title":"BMC Nephrol."},{"key":"55561_CR27","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1186\/s12882-017-0605-7","volume":"18","author":"Y Liu","year":"2017","unstructured":"Liu, Y., Ma, X., Zheng, J., Jia, J. & Yan, T. Effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on cardiovascular events and residual renal function in dialysis patients: a meta-analysis of randomised controlled trials. BMC Nephrol. 18, 206 (2017).","journal-title":"BMC Nephrol."},{"key":"55561_CR28","doi-asserted-by":"crossref","unstructured":"Zhang, L., Zeng, X., Fu, P. & Wu, H. M. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for preserving residual kidney function in peritoneal dialysis patients. Cochrane Database Syst Rev. CD009120 (2014).","DOI":"10.1002\/14651858.CD009120.pub2"},{"key":"55561_CR29","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1177\/089686080902900514","volume":"29","author":"A Akbari","year":"2009","unstructured":"Akbari, A. et al. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in peritoneal dialysis: systematic review and meta-analysis of randomized controlled trials. Perit Dial Int. 29, 554\u2013561 (2009).","journal-title":"Perit Dial Int."},{"key":"55561_CR30","doi-asserted-by":"publisher","first-page":"379","DOI":"10.3747\/pdi.2014.00279","volume":"35","author":"AY Wang","year":"2015","unstructured":"Wang, A. Y. et al. ISPD Cardiovascular and Metabolic Guidelines in Adult Peritoneal Dialysis Patients Part I - Assessment and Management of Various Cardiovascular Risk Factors. Perit Dial Int. 35, 379\u2013387 (2015).","journal-title":"Perit Dial Int."},{"key":"55561_CR31","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1016\/S0272-6386(04)00954-0","volume":"44","author":"B Phakdeekitcharoen","year":"2004","unstructured":"Phakdeekitcharoen, B. & Leelasa-nguan, P. Effects of an ACE inhibitor or angiotensin receptor blocker on potassium in CAPD patients. Am J Kidney Dis. 44, 738\u2013746 (2004).","journal-title":"Am J Kidney Dis."},{"key":"55561_CR32","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1177\/089686089201200304","volume":"12","author":"A Favazza","year":"1992","unstructured":"Favazza, A. et al. Peritoneal clearances in hypertensive CAPD patients after oral administration of clonidine, enalapril, and nifedipine. Perit Dial Int. 12, 287\u2013291 (1992).","journal-title":"Perit Dial Int."},{"key":"55561_CR33","first-page":"605","volume":"4","author":"J Wang","year":"2005","unstructured":"Wang, J. & Xiao, M. Y. Protective effects of valsartan on residual renal function in patients on CAPD. Chinese. Journal of Blood Purification. 4, 605\u2013606 (2005).","journal-title":"Journal of Blood Purification."},{"key":"55561_CR34","first-page":"413","volume":"23","author":"H Zhong","year":"2007","unstructured":"Zhong, H. et al. Effcts of irbesartan on residual renal function in peritoneal dialysis patients. Chin J Nephrol. 23, 413\u2013416 (2007).","journal-title":"Chin J Nephrol."},{"key":"55561_CR35","unstructured":"Wontanatawatot. The effect of enalapril and losartan on peritoneal membrane in continuous ambulatory peritoneal dialysis patients. Master of Science Program in Medicine thesis, Chulalongkorn University (2009)."},{"key":"55561_CR36","first-page":"315","volume":"64","author":"FA Reyes-Marin","year":"2012","unstructured":"Reyes-Marin, F. A., Calzada, C., Ballesteros, A. & Amato, D. Comparative study of enalapril vs. losartan on residual renal function preservation in automated peritoneal dialysis. A randomized controlled study. Rev Invest Clin. 64, 315\u2013321 (2012).","journal-title":"Rev Invest Clin."},{"key":"55561_CR37","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1177\/089686080302300311","volume":"23","author":"DW Johnson","year":"2003","unstructured":"Johnson, D. W. et al. Predictors of decline of residual renal function in new peritoneal dialysis patients. Perit Dial Int. 23, 276\u2013283 (2003).","journal-title":"Perit Dial Int."},{"key":"55561_CR38","doi-asserted-by":"publisher","first-page":"180","DOI":"10.3747\/pdi.2013.00075","volume":"35","author":"CC Szeto","year":"2015","unstructured":"Szeto, C. C. et al. Predictors of residual renal function decline in patients undergoing continuous ambulatory peritoneal dialysis. Perit Dial Int. 35, 180\u2013188 (2015).","journal-title":"Perit Dial Int."},{"issue":"Suppl 2","key":"55561_CR39","first-page":"S188","volume":"89","author":"V Jearnsujitwimol","year":"2006","unstructured":"Jearnsujitwimol, V., Eiam-Ong, S., Kanjanabuch, T., Wathanavaha, A. & Pansin, P. The effect of angiotensin II receptor blocker on peritoneal membrane transports in continuous ambulatory peritoneal dialysis patients. J Med Assoc Thai. 89(Suppl 2), S188\u2013195 (2006).","journal-title":"J Med Assoc Thai."},{"key":"55561_CR40","doi-asserted-by":"publisher","DOI":"10.1186\/s13643-015-0133-0","volume":"4","author":"C Cameron","year":"2015","unstructured":"Cameron, C. et al. Network meta-analysis incorporating randomized controlled trials and non-randomized comparative cohort studies for assessing the safety and effectiveness of medical treatments: challenges and opportunities. Syst Rev. 4, 147 (2015).","journal-title":"Syst Rev."},{"key":"55561_CR41","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.1056\/NEJM199311113292004","volume":"329","author":"EJ Lewis","year":"1993","unstructured":"Lewis, E. J., Hunsicker, L. G., Bain, R. P. & Rohde, R. D. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med. 329, 1456\u20131462 (1993).","journal-title":"N Engl J Med."},{"key":"55561_CR42","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1056\/NEJM199403313301301","volume":"330","author":"S Klahr","year":"1994","unstructured":"Klahr, S. et al. The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. Modification of Diet in Renal Disease Study Group. N Engl J Med. 330, 877\u2013884 (1994).","journal-title":"N Engl J Med."},{"key":"55561_CR43","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1046\/j.1523-1755.2000.00880.x","volume":"57","author":"S Andersen","year":"2000","unstructured":"Andersen, S., Tarnow, L., Rossing, P., Hansen, B. V. & Parving, H. H. Renoprotective effects of angiotensin II receptor blockade in type 1 diabetic patients with diabetic nephropathy. Kidney Int. 57, 601\u2013606 (2000).","journal-title":"Kidney Int."},{"key":"55561_CR44","unstructured":"Methods Guide for Effectiveness and Comparative Effectiveness Reviews. AHRQ Publication No. 10(14)-EHC063-EF. Chapters available at, http:\/\/www.effectivehealthcare.ahrq.gov. Agency for Healthcare Research and Quality (US), January 2014."},{"key":"55561_CR45","doi-asserted-by":"publisher","first-page":"777","DOI":"10.7326\/M14-2385","volume":"162","author":"B Hutton","year":"2015","unstructured":"Hutton, B. et al. The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann Intern Med. 162, 777\u2013784 (2015).","journal-title":"Ann Intern Med."},{"key":"55561_CR46","doi-asserted-by":"publisher","unstructured":"Higgins, J. et al. In Cochrane Methods (eds J. Chandler, J. McKenzie, I. Boutron, & V. Welch). Cochrane Database of Systematic Reviews 2016, Issue 10 (Suppl 1), https:\/\/doi.org\/10.1002\/14651858.CD201601.","DOI":"10.1002\/14651858.CD201601."},{"key":"55561_CR47","unstructured":"Wells, G. et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Available at, http:\/\/www.ohri.ca\/programs\/clinical_epidemiology\/oxford.asp. Accessed June 29, 2019."},{"key":"55561_CR48","unstructured":"Cohen, J. Statistical power analysis for the behavioral sciences. 2nd edn, (Lawrence Erlbaum Associates, 1988)."},{"key":"55561_CR49","doi-asserted-by":"crossref","unstructured":"Chaimani, A., Salanti, G., Leucht, S., Geddes, J. R. & Cipriani, A. Common pitfalls and mistakes in the set-up, analysis and interpretation of results in network meta-analysis: what clinicians should look for in a published article. Evid Based Ment Health. pii: ebmental-2017-102753. (2017 Jul 24.).","DOI":"10.1136\/eb-2017-102753"},{"key":"55561_CR50","doi-asserted-by":"publisher","first-page":"f2914","DOI":"10.1136\/bmj.f2914","volume":"346","author":"EJ Mills","year":"2013","unstructured":"Mills, E. J., Thorlund, K. & Ioannidis, J. P. Demystifying trial networks and network meta-analysis. BMJ. 346, f2914 (2013).","journal-title":"BMJ."},{"key":"55561_CR51","doi-asserted-by":"publisher","first-page":"e1001454","DOI":"10.1371\/journal.pmed.1001454","volume":"10","author":"J Barth","year":"2013","unstructured":"Barth, J. et al. Comparative efficacy of seven psychotherapeutic interventions for patients with depression: a network meta-analysis. PLoS Med. 10, e1001454 (2013).","journal-title":"PLoS Med."},{"key":"55561_CR52","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.jclinepi.2014.08.012","volume":"68","author":"KM Rhodes","year":"2015","unstructured":"Rhodes, K. M., Turner, R. M. & Higgins, J. P. Predictive distributions were developed for the extent of heterogeneity in meta-analyses of continuous outcome data. J Clin Epidemiol. 68, 52\u201360 (2015).","journal-title":"J Clin Epidemiol."},{"key":"55561_CR53","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1093\/ije\/dys041","volume":"41","author":"RM Turner","year":"2012","unstructured":"Turner, R. M., Davey, J., Clarke, M. J., Thompson, S. G. & Higgins, J. P. Predicting the extent of heterogeneity in meta-analysis, using empirical data from the Cochrane Database of Systematic Reviews. Int J Epidemiol. 41, 818\u2013827 (2012).","journal-title":"Int J Epidemiol."},{"key":"55561_CR54","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1093\/ije\/dys222","volume":"42","author":"AA Veroniki","year":"2013","unstructured":"Veroniki, A. A., Vasiliadis, H. S., Higgins, J. P. & Salanti, G. Evaluation of inconsistency in networks of interventions. Int J Epidemiol. 42, 332\u2013345 (2013).","journal-title":"Int J Epidemiol."},{"key":"55561_CR55","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1002\/jrsm.57","volume":"3","author":"A Chaimani","year":"2012","unstructured":"Chaimani, A. & Salanti, G. Using network meta-analysis to evaluate the existence of small-study effects in a network of interventions. Res Synth Methods. 3, 161\u2013176 (2012).","journal-title":"Res Synth Methods."},{"key":"55561_CR56","doi-asserted-by":"publisher","first-page":"i5396","DOI":"10.1136\/bmj.i5396","volume":"355","author":"M Woodhead","year":"2016","unstructured":"Woodhead, M. 80% of China\u2019s clinical trial data are fraudulent, investigation finds. BMJ. 355, i5396 (2016).","journal-title":"BMJ."},{"key":"55561_CR57","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1038\/nature.2017.21977","volume":"545","author":"D Cyranoski","year":"2017","unstructured":"Cyranoski, D. China cracks down on fake data in drug trials. Nature. 545, 275 (2017).","journal-title":"Nature."},{"key":"55561_CR58","doi-asserted-by":"publisher","first-page":"2161","DOI":"10.1002\/sim.1207","volume":"21","author":"F Curtin","year":"2002","unstructured":"Curtin, F., Elbourne, D. & Altman, D. G. Meta-analysis combining parallel and cross-over clinical trials. III: The issue of carry-over. Stat Med. 21, 2161\u20132173 (2002).","journal-title":"Stat Med."},{"key":"55561_CR59","doi-asserted-by":"publisher","first-page":"e0159014","DOI":"10.1371\/journal.pone.0159014","volume":"11","author":"SJ Nolan","year":"2016","unstructured":"Nolan, S. J., Hambleton, I. & Dwan, K. The Use and Reporting of the Cross-Over Study Design in Clinical Trials and Systematic Reviews: A Systematic Assessment. PLoS One. 11, e0159014 (2016).","journal-title":"PLoS One."},{"key":"55561_CR60","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1016\/j.jclinepi.2014.11.023","volume":"68","author":"ND Berkman","year":"2015","unstructured":"Berkman, N. D. et al. Grading the strength of a body of evidence when assessing health care interventions: an EPC update. J Clin Epidemiol. 68, 1312\u20131324 (2015).","journal-title":"J Clin Epidemiol."},{"key":"55561_CR61","doi-asserted-by":"publisher","first-page":"g5630","DOI":"10.1136\/bmj.g5630","volume":"349","author":"MA Puhan","year":"2014","unstructured":"Puhan, M. A. et al. A GRADE Working Group approach for rating the quality of treatment effect estimates from network meta-analysis. BMJ. 349, g5630 (2014).","journal-title":"BMJ."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-55561-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-55561-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-55561-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,17]],"date-time":"2022-12-17T17:44:34Z","timestamp":1671299074000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-55561-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12,20]]},"references-count":61,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,12]]}},"alternative-id":["55561"],"URL":"https:\/\/doi.org\/10.1038\/s41598-019-55561-5","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12,20]]},"assertion":[{"value":"17 July 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 November 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 December 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"19582"}}